RANKL inhibitor monoclonal antibody

This page covers all RANKL inhibitor monoclonal antibody drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand).

Targets

RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand)

Phase 3 pipeline (2)

• ABP 654 · Amgen · Bone metabolism / Oncology
  ABP 654 is a monoclonal antibody that blocks RANKL (receptor activator of nuclear factor kappa-B ligand) to inhibit osteoclast formation and bone resorption.
• AMG 162 · Amgen · Bone metabolism / Oncology
  AMG 162 is a monoclonal antibody that inhibits RANKL (receptor activator of nuclear factor kappa-B ligand), blocking osteoclast formation and bone resorption.